Drug intelligence / Profile preview

mRNA for Ophthalmic

Development stage: Preclinical
Lead developer: NANO mRNA
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Ophthalmic

Overview

mRNA for Ophthalmic is a preclinical-stage therapeutic program developed by NANO mRNA. It utilizes messenger RNA (mRNA) technology to treat various ophthalmic diseases. The approach involves delivering mRNA to ocular tissues to induce the expression of specific therapeutic proteins. While the exact molecular targets and specific indications within ophthalmology have not been disclosed, the program leverages the company's specialized delivery platforms for nucleic acid medicine.

Other names: messenger RNA for ophthalmicmRNA-Ophthalmic diseases

Beyond the preview

Go deeper on mRNA for Ophthalmic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA for Ophthalmic.

Explore the full profile